SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-19-000464
Filing Date
2019-03-29
Accepted
2019-03-29 17:20:47
Documents
109
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F nymx_20f.htm 20-F 886872
2 EX-12 (A) nymx_ex12a.htm EX-12.A 8505
3 EX-12 (B) nymx_ex12b.htm EX-12.B 8162
4 EX-13 (A) nymx_ex13a.htm EX-13.A 2381
5 EX-13 (B) nymx_ex13b.htm EX-13.B 2348
  Complete submission text file 0001640334-19-000464.txt   5388292

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nymx-20181231.xml EX-101.INS 1237168
7 XBRL TAXONOMY EXTENSION SCHEMA nymx-20181231.xsd EX-101.SCH 98772
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20181231_cal.xml EX-101.CAL 50434
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20181231_def.xml EX-101.DEF 189840
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20181231_lab.xml EX-101.LAB 355457
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20181231_pre.xml EX-101.PRE 309815
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 19717746
SIC: 2835 In Vitro & In Vivo Diagnostic Substances